Evidence map›Paper›PMID 32915170›Full record

ReviewRevista espanola de salud publica2020

[Statement of the Spanish Interdisciplinary Vascular Prevention Committee on the updated European Cardiovascular Prevention Guidelines.]

Pedro Armario, Carlos Brotons, Roberto Elosua, Maria Alonso de Leciñana, Almudena Castro, Albert Clarà, Olga Cortés, Ángel Díaz Rodriguez, María Herranz, Soledad Justo and 7 more

Open access · greenAbstract readReview
In one paragraph

Review in Revista espanola de salud publica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 10 institutions in 1 country.

Pedro ArmarioSociedad Española-Liga Española para la Lucha contra la Hipertensión Arterial.
Carlos BrotonsSociedad Española de Medicina Familiar y Comunitaria.
Roberto ElosuaSociedad Española de Epidemiología.
Maria Alonso de LeciñanaSociedad Española de Neurología.
Almudena CastroSociedad Española de Cardiología-Coordinadora Nacional Sección de Prevención.
Albert ClaràSociedad Española de Angiología y Cirugía Vascular.
Olga CortésAsociación Española Pediatría de Atención Primaria.
Ángel Díaz RodriguezSociedad Española de Médicos de Atención Primaria-Semergen.
María HerranzFederación de Asociaciones de Enfermería Comunitaria y Atención Primaria-FAECAP.
Soledad JustoMinisterio de Sanidad. Madrid. España.
Carlos LahozSociedad Española de Medicina Interna.
Juan Pedro-BotetSociedad Española de Arteriosclerosis.
Antonio Pérez PérezSociedad Española de Diabetes.
Rafael SantamariaSociedad Española de Nefrología.
Ricard TresserrasSociedad Española de Salud Pública y Administración Sanitaria-SESPAS.
Susana Aznar LainGrupo de Investigación PAFS (Promoción de la Actividad Física para la Salud). Facultad de Ciencias del Deporte. Universidad de Castilla-La Mancha. Toledo. España.
Miguel Ángel Royo-BordonadaInstituto de Salud Carlos III. Madrid. España.
Sociedad Española de Medicina Interna · ESSociedad Española de Nefrología · ESAsociación Española de Urología · ESConsejería de Educación de la Junta de Castilla y León · ESInstituto de Salud Carlos III · ESMinisterio de Transportes, Movilidad y Agenda Urbana · ESServicio de Salud de Castilla La Mancha · ESSociedad Andaluza de Medicina Familiar y Comunitaria · ESSociedad Española de Cardiología · ESSociedad Española de Cirugía Pediátrica · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present the adaptation for Spain of the updated European Cardiovascular Prevention Guidelines. In this update, greater stress is laid on the population approach, and especially on the promotion of physical activity and healthy diet through dietary, leisure and active transport policies in Spain. To estimate vascular risk, note should be made of the importance of recalibrating the tables used, by adapting them to population shifts in the prevalence of risk factors and incidence of vascular diseases, with particular attention to the role of chronic kidney disease. At an individual level, the key element is personalised support for changes in behaviour, adherence to medication in high-risk individuals and patients with vascular disease, the fostering of physical activity, and cessation of smoking habit. Furthermore, recent clinical trials with PCSK9 inhibitors are reviewed, along with the need to simplify pharmacological treatment of arterial hypertension to improve control and adherence to treatment. In the case of patients with type 2 diabetes mellitus and vascular disease or high vascular disease risk, when lifestyle changes and metformin are inadequate, the use of drugs with proven vascular benefit should be prioritised. Lastly, guidelines on peripheral arterial disease and other specific diseases are included, as is a recommendation against prescribing antiaggregants in primary prevention.

Indexed as

PCSK9 InhibitorsCardiologyCardiovascular DiseasesDiabetes Mellitus, Type 2DietExerciseHumansKidney Failure, ChronicLife StyleMedication AdherenceMetforminPractice Guidelines as TopicPrimary PreventionProprotein Convertase 9Risk FactorsSmoking CessationMetforminPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9Arterial hypertensionClinical practice guidelinesDiabetesHealthy dietLipid controlPrevention and controlSmokingSpainVascular diseases

Identifiers

PMID32915170
PMCPMC11618292
OpenAlexW3085306855

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.